Neovasc (NSDQ:NVCN) said late yesterday that it resolved the last remaining patent litigation between it and Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies by adding members of CardiAQ as co-inventors of the patents in dispute. Vancouver-based Neovasc said that it added CardiAQ’s Jeremy Brent Ratz and Arshad Quadri as co-inventors of three patents, each of which was related […]
Neovasc gains on Reducer study
Shares of Neovasc (NSDQ:NVCN) are up today after the medical device company released study results showing that its Reducer device for treating angina doesn’t worsen heart function and may in fact help. The Vancouver-based company said the 24-patient study of patients treated with Reducer, which is designed to narrow the coronary sinus, showed no significant […]
Neovasc shares tumble on 2018 earnings release
Shares in Neovasc (NSDQ:NVCN) have fallen nearly 10% today after the medical device maker posted full year 2018 earnings that showed losses growing to more than triple what it reported in 2017. The Vancouver-based company posted losses of $109.1 million, or $7.63 per share, on sales of $1.7 million, seeing losses grow 338.7% while sales shrunk […]
Neovasc claims win in German TMVR patent case against Edwards unit CardiAQ Valve
Neovasc (NSDQ:NVCN) today claimed a win in its patent infringement war with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies, saying a German appeals court dismissed a case there. In June 2017 the District Court in Munich ruled that CardiAQ Valve contributed to the creation of Neovasc’s Tiara transcatheter mitral valve replacement, awarding”co-entitlement” rights to the patent in […]
Neovasc retains EC Marking after EU surveillance audit
Updated to correct from CE Marking to EC Marking. Neovasc (NSDQ:NVCN) said yesterday that it successfully completed its 2019 mandatory surveillance audit with its notified body in the European Union. The Vancouver-based company said that as a result of the successful audit, and its maintenance of the ISO 13485: 2016 certification of its quality management system, […]
Neovasc prices $5m offering
Neovasc (NSDQ:NVCN) today priced an upcoming offering looking to raise $5 million to support its Tiara and Reducer devices. In the round, the Vancouver-based company will look to float approximately 11.1 million shares of its common stock at a price of 45¢ per share. The offering is expected to close on March 15, the company said. […]
Neovasc advances warrant exchange from CardiAQ case
Neovasc (NSDQ:NVCN) said today that it inked an exchange deal for the last of the warrants it issued as part of a $65 million funding round to cover the damages from litigation with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve. The Vancouver-based replacement heart valve developer said it plans to exchange the Series A and Series E warrants it […]
Neovasc prices $5m offering
Neovasc (NSDQ:NVCN) today priced a $5 million offering of its common stock slated to support its Reducer device and Tiara transcatheter mitral valve. The Vancouver-based company said it plans to float approximately 11.1 million shares of its common stock at a price of 45¢ per share, expecting to bring in approximately $5 million in gross proceeds. […]
Neovasc inks $3m settlement deal with MID, raises $1m
Neovasc (NSDQ:NVCN) said today that it inked a $3 million settlement agreement with Micro Interventional Devices to resolve undisclosed allegations related to Neovasc’s transcatheter mitral valve replacement technology, including its flagship Tiara device, and added that it has raised approximately $1.2 million. The agreement includes payments totally approximately $3 million to be made by Neovasc to […]
Neovasc jumps on Tiara trial news
Neovasc (NSDQ:NVCN) said today that it won approval to advance a clinical trial for its Tiara transcatheter mitral valve replacement, sending its share price up on Wall Street. The Vancouver-based company said it closed out the Phase I requirements for the 115-patient Tiara-II trial in the U.K. and Germany, after several reviews. The Clinical Events Committee […]
Neovasc touts Reducer study
Neovasc (NSDQ:NVCN) this week touted a newly-published article that described the use of dipyridamole stress perfusion cardiac magnetic resonance to evaluate its Reducer device. The Vancouver-based company’s device is designed to treat refractory angina. The article, published in the Journal of the American College of Cardiology: Cardiovascular Interventions, featured a 66 year old man with angina who […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube